Photo from wikipedia
Abstract Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving… Click to show full abstract
Abstract Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission.
Keywords:
severe acute;
coronavirus;
tixagevimab cilgavimab;
cilgavimab;
acute respiratory;
respiratory syndrome
Journal Title: Open Forum Infectious Diseases
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Open Forum Infectious Diseases
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!